News - Dainippon Sumitomo Pharma, Genetics

Filter

Popular Filters

1 to 25 of 52 results

Sunovion’s once-daily epilepsy drug Aptiom debuts in USA

08-04-2014

USA-based Sunovion Pharmaceuticals, a subsidiary of Japanese drug major Dainippon Sumitomo, has launched…

AptiomDainippon Sumitomo PharmaMarkets & MarketingNeurologicalNorth AmericaPharmaceuticalSunovionUSA

EU approval for Dainippon Sumitomo and Takeda’s Latuda

EU approval for Dainippon Sumitomo and Takeda’s Latuda

28-03-2014

Japanese drug majors Dainippon Sumitomo Pharma and Takeda Pharmaceutical have received European Commission…

Dainippon Sumitomo PharmaEuropeLatudaNeurologicalPharmaceuticalRegulationSunovionTakeda Pharmaceuticals

Oxford Gene Technology acquires Cytocell to expand genomics offering

Oxford Gene Technology acquires Cytocell to expand genomics offering

04-03-2014

Genetic research company Oxford Gene Technology has acquired Cambridge-based Cytocell, a leading provider…

BiotechnologyGeneticsMergers & AcquisitionsOxford Gene TechnologyUK

FDA approves Northera for neurogenic orthostatic hypotension

FDA approves Northera for neurogenic orthostatic hypotension

19-02-2014

Shares of US biotech firm Chelsea Therapeutics soared 38% to $6.75 in after-hours trading yesterday,…

BiotechnologyChelsea TherapeuticsDainippon Sumitomo PharmaNorth AmericaNortheraRare diseasesRegulationUSA

NicOx appoints financial partner to assess Duchenne Muscular Dystrophy treatment

14-02-2014

French biotechnology firm NicOx (Euronext Paris: COX) has granted an undisclosed financial partner an…

BiotechnologyFranceGeneticsLicensingnaproxcinodNicOx

Ipsen’s Dysport next generation shows safety and efficacy in Phase III

Ipsen’s Dysport next generation shows safety and efficacy in Phase III

05-02-2014

French drugmaker Ipsen today announced the results of the international Phase III clinical trial of Dysport…

DysportFranceGeneticsIpsenPharmaceuticalResearch

Edison Pharma in deal with Dainippon Sumitomo potentially worth $4.3 billion

Edison Pharma in deal with Dainippon Sumitomo potentially worth $4.3 billion

31-01-2014

Privately-held US company Edison Pharmaceuticals has entered into a new strategic alliance valued up…

Dainippon Sumitomo PharmaEdison PharmaceuticalsEPI-589LicensingMetabolicsNeurologicalPharmaceutical

UCB launches online search for rare phenotypes

UCB launches online search for rare phenotypes

28-01-2014

Belgian drugmaker UCB (Euronext Brussels: UCB) has launched an online search to find rare phenotypes…

GeneticsGlobalPharmaceuticalRare diseasesResearchUCB

Intercept rockets on positive liver disease drug trial

10-01-2014

Shares of USA-based Intercept Pharmaceuticals tripled to $275.87 by close of trading on January 9, when…

Dainippon Sumitomo PharmaIntercept PharmaceuticalsNephrology and Hepatologyobeticholic acidPharmaceuticalResearch

Nuevolution signs licensing agreement with Novartis

Nuevolution signs licensing agreement with Novartis

10-01-2014

Denmark-based Nuevolution has entered into a non-exclusive technology licensing agreement with Swiss…

BiotechnologyDenmarkGeneticsLicensingNorthern EuropeNovartisNuevolutionResearch

FDA thumbs up for Sunovion’s Aptiom as once-daily adjunctive for partial-onset seizures

FDA thumbs up for Sunovion’s Aptiom as once-daily adjunctive for partial-onset seizures

09-11-2013

The US Food and Drug Administration on Friday approved Sunovion Pharmaceutical’s (a subsidiary of Japanese…

AptiomDainippon Sumitomo PharmaNeurologicalNorth AmericaPharmaceuticalRegulationSunovion

Report: Latuda has greatest commercial potential among new agents entering the bipolar drug market

Report: Latuda has greatest commercial potential among new agents entering the bipolar drug market

15-10-2013

Dainippon Sumitomo Pharma/Sunovion/Takeda Pharmaceutical’s atypical antipsychotic Latuda (lurasidone)…

Dainippon Sumitomo PharmaGlobalLatudaMarkets & MarketingNeurologicalPharmaceuticalTakeda Pharmaceuticals

Scotland demonstrates its collaborative approach to cell therapy development

Scotland demonstrates its collaborative approach to cell therapy development

14-10-2013

Scottish stem cell companies Sistemic and Roslin Cells say they are working together with c to make the…

BiotechnologyEuropeGeneticsResearchRoslin CellsSistemic

arGEN-X R&D milestone triggers payment from Shire

19-09-2013

Belgium-based preclinical stage biotech firm arGEN-X has announced a key milestone in its SIMPLE Antibody…

arGEN-XBiotechnologyEuropeFinancialGenetics

Sunovion's eslicarbazepine successful in Ph III epilepsy studies

18-09-2013

Sunovion Pharmaceuticals, a US subsidiary of Japan's Dainippon Sumitomo Pharma (TYO: 4506), says that…

Dainippon Sumitomo PharmaeslicarbazepineNeurologicalPharmaceuticalResearchSunovion

US regenerative medicine market to increase at a CAGR of 15.8%

03-09-2013

The US regenerative medicine market has been forecast to increase at a compound annual growth rate (CAGR)…

BiotechnologyGeneticsMarkets & MarketingNorth America

Potential Duchenne drug expected to complete phase III trial this year

16-08-2013

Dutch biotech company Prosensa says it has made progress with its Duchenne treatments, with six exon…

drisapersenEuropeGeneticsGlaxoSmithKlinePharmaceuticalProsensaResearch

Takeda gains first European approval for lurasidone

14-08-2013

Japan's largest drugmaker Takeda Pharma (TYO: 4502) says it has been granted approval by Switzerland's…

Dainippon Sumitomo PharmaEuropeLatudalurasidoneNeurologicalPharmaceuticalRegulationTakeda Pharmaceuticals

Sunovion announces novel drug discovery partnership

14-08-2013

Sunovion Pharmaceuticals, a wholly-owned US subsidiary of Japanese drug major Dainippon Sumitomo Pharma…

AfraxisDainippon Sumitomo PharmaLicensingNeurologicalPharmaceuticalResearchSunovion

Dainippon Sumitomo establishes regenerative and cellular medicine office

12-08-2013

Japanese drug major Dainippon Sumitomo Pharma (TYO: 4506) says that it has set up the Regenerative &…

Asia-PacificBiotechnologyDainippon Sumitomo PharmaPharmaceuticalProductionResearch

Top-line financials for Japanese drug majors

01-08-2013

Among a flurry of first-quarter fiscal 2013/14 financial results released by Japanese drug majors, the…

Dainippon Sumitomo PharmaEisaiFinancialMitsubishi TanabePharmaceuticalTakeda Pharmaceuticals

Stem cell company ReNeuron gets backing from Welsh government

22-07-2013

UK-based stem cell company ReNeuron (AIM: RENE) will relocate to Wales after Arthurian Life Sciences,…

BiotechnologyEuropeFinancialGeneticsReNeuron

1 to 25 of 52 results

Back to top